Notice 13 Feb 2025 mylan inc., pharmaceutical industry, regulatory compliance, drug enforcement administration, controlled substances

💊Mylan Inc. Seeks Registration for Controlled Substance Importing

Mylan Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Learn More
Compliance, Regulatory Action 31 Jan 2025 regulatory compliance, business operations, pharmaceutical industry, oregon, controlled substances, drug enforcement

⚖️DOJ Notice on Organic Consultants LLC Controlled Substances Application

Organic Consultants LLC DBA Cascade Chemistry has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Learn More
Regulatory Compliance, Industry Standards 17 Jan 2025 regulatory compliance, fda, pharmaceutical industry, drug master file, abbreviated new drug applications

💊FDA Notice on Type V Drug Master Files for ANDA Support

The Food and Drug Administration (FDA or Agency), Center for Drug Evaluation and Research (CDER), Office of Generic Drugs is establishing a public docket entitled "Use of a Type V Drug Master File (DMF) for Model Master File (MMF) Submissions to Support Abbreviated New Drug Applications (ANDAs)." The purpose of this docket to solicit input from interested parties on this topic.

Learn More
Compliance, Regulatory Requirements, Business Incentives 2 Jan 2025 advanced manufacturing, manufacturing processes, drug quality, fda, pharmaceutical industry

⚙️FDA Guidance on Advanced Manufacturing Technologies for Pharmaceuticals

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Advanced Manufacturing Technologies Designation Program." FDA encourages the early adoption of advanced manufacturing technologies (AMTs) by the pharmaceutical industry, which can improve the reliability and robustness of the manufacturing process and can benefit patients by enhancing product quality and reducing drug development time or increasing or maintaining the supply of drugs that are life-supporting, life-sustaining, of critical importance to providing health care, or in shortage. This guidance provides recommendations to persons and organizations interested in participating in FDA's Advanced Manufacturing Technologies Designation Program, which facilitates the development of drugs manufactured using an AMT that has been designated as such under the program. The guidance finalizes the draft guidance of the same title issued on December 13, 2023.

Learn More